Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Ce...
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: Yahoo! Finance
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase 1b trial will be featured in an oral presentation at IDWeek 2025, taking place October 19–22 in Atlanta, Georgia. Presentation Details Abstract ID: Title: Clinical and Microbiology Outcomes of Bloodstream Infections (BSI) in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HCT) in a Randomized, Double-blind, Placebo-controlled Cohort 2 of a Phase 1b Study of SER-155, an Investigation Live Biotherapeutic Presenter: Tessa Andermann, MD, MPH; Associate Professor of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine Session: Blood and Guts – Microbiome Discoveries Date and Time: October 20, 10:30-10:42am EDT Location: B207-B208, Georgia World Congress Center The presentation will in
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics to Participate in Piper Sandler Healthcare ConferenceGlobeNewswire
- Seres Therapeutics (NASDAQ:MCRB) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire
- Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025GlobeNewswire
- Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155GlobeNewswire
MCRB
Earnings
- 11/5/25 - Beat
MCRB
Analyst Actions
- 9/24/25 - Canaccord Genuity
MCRB
Sec Filings
- 11/18/25 - Form 4
- 11/18/25 - Form 4
- 11/18/25 - Form 4
- MCRB's page on the SEC website